■本研究通过病例系列和文献综述探讨肿瘤诱导的骨软化症(TIO),评估18F-AlF-NOTA-奥曲肽(18F-OC)正电子发射断层扫描/计算机断层扫描(PET/CT)的诊断潜力。
■我们分析了接受18F-OCPET/CT的TIO患者。肿瘤尺寸等参数,最大标准化摄取值(SUVmax),我们仔细评估了平均标准化摄取值(SUVmean)和代谢性肿瘤体积(MTV).回顾了与TIO相关的临床特征和影像学特征。
■6例临床怀疑TIO的患者出现低磷血症(0.25至0.64mmol/L),碱性磷酸酶(ALP)水平升高(142至506U/L),甲状旁腺激素(PTH)水平升高(92.9至281.7pg/mL)。在这些病人中,两人接受了FGF-23测试,结果为3185.00pg/ml和17.56pg/ml,分别。传统的成像方式描绘了广泛的骨质疏松症,一些病例显示骨折表明骨软化和相关的病理性骨折。随后的18F-OCPET/CT促进了致病肿瘤的精确定位,组织病理学检查证实了磷性间充质肿瘤(PMT)的诊断。从最初的临床表现到明确的TIO诊断的间隔大约为2.5年(范围:1-4年),肿瘤大小不同(最大直径:7.8至40.0毫米),SUVmax(5.47至25.69),SUVmean(3.43至7.26),和MTV(1.27至18.59cm3)。
■全身18F-OCPET/CT成像的实施成为识别引起TIO的隐匿性肿瘤的关键工具。未来纳入更广泛队列的研究对于进一步描述18F-OCPET/CT在TIO管理中的诊断和治疗意义至关重要。
UNASSIGNED: This study explores tumor-induced osteomalacia (TIO) through a case series and literature
review, assessing the diagnostic potential of 18F-AlF-NOTA-octreotide (18F-OC) positron emission tomography/computed tomography (PET/CT).
UNASSIGNED: We analyzed TIO patients who underwent 18F-OC PET/CT. Parameters such as tumor dimension, the maximum standardized uptake value (SUVmax), the mean standardized uptake value (SUVmean) and metabolic tumor volume (MTV) were meticulously assessed. Clinical features and imaging characteristics pertinent to TIO were reviewed.
UNASSIGNED: 6 patients with clinical suspicion of TIO exhibited hypophosphatemia (0.25 to 0.64 mmol/L), elevated alkaline phosphatase (ALP) levels (142 to 506 U/L), and increased parathyroid hormone (PTH) levels (92.9 to 281.7 pg/mL). Of these patients, two underwent FGF-23 testing, with results of 3185.00 pg/ml and 17.56 pg/ml, respectively. Conventional imaging modalities depicted widespread osteoporosis, with several cases demonstrating fractures indicative of osteomalacic and associated pathological fractures. Subsequent 18F-OC PET/CT facilitated the accurate localization of causative tumors, with histopathological examination confirming the diagnosis of phosphaturic mesenchymal tumor (PMT). The interval from initial clinical presentation to definitive TIO diagnosis spanned approximately 2.5 years (range: 1 - 4 years), with tumors varying in size (maximum diameter: 7.8 to 40.0 mm), SUVmax (5.47 to 25.69), SUVmean (3.43 to 7.26), and MTV (1.27 to 18.59 cm3).
UNASSIGNED: The implementation of whole-body 18F-OC PET/CT imaging emerges as a critical tool in the identification of occult tumors causing TIO. Future investigations incorporating a broader cohort are imperative to further delineate the diagnostic and therapeutic implications of 18F-OC PET/CT in managing TIO.